bis-ethanolamine pyrophosphate | 64918-94-1

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机含氧阴离子化合物
• 英文名称: bis-ethanolamine pyrophosphate
• 英文别名: Ethanolamine pyrophosphate；2-aminoethanol;phosphono dihydrogen phosphate
• CAS: 64918-94-1
• 化学式: 2C₂H₈NO*H₂O₇P₂
• 分子量: 300.142
• InChiKey: NXDMQSHELLPPIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.87
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  171
• 氢给体数：
  6
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  C.I.酸性橙108 在 焦磷酸 作用下， 以 水 为溶剂， 反应 0.33h， 以528 mg的产率得到bis-ethanolamine pyrophosphate
  参考文献：
  名称：

  [EN] ORAL PYROPHOSPHATE FOR USE IN REDUCING CALCIFICATION
  [FR] PYROPHOSPHATE ORAL DESTINÉ À ÊTRE UTILISÉ DANS LA RÉDUCTION DE LA CALCIFICATION

  摘要：

  The current invention relates to use of oral pyrophosphate wherein said pyrophosphate is selected from the group consisting of monoarginine pyrophosphate, monolysine pyrophosphate, dipotassium pyrophosphate, bisethanolamine pyrophosphate and bisammonium pyrophosphate for preventing and/or reducing tissue calcification, particularly soft tissue calcification, and/or diseases or disorders characterized by low plasma PPi levels, as, e.g., occurs in chronic kidney disease (CKD), end-stage renal disease (ESRD), generalized arterial calcification of infancy (GACI), Pseudoxanthoma elasticum (PXE), Arterial Calcification Due to Deficiency of CD73 (ACDC), Ehlers-Danlos syndrome, arteriosclerosis obliterans, venous calcifications, crystal deposition disorders, calcification resulting from neurological disorders, calcinosis universalis, calcinosis circumscripta, scleroderma, dermatomyositis, systemic lupus erythematosus, hyperparathyroidism, neoplasms, milk-alkali syndrome, hypervitaminosis D, tumoral calcinosis, hypophosphatemic rickets, ossification of the posterior longitudinal ligament of the spine, myocardial ischemia, joint calcification, heterotropic ossification of traumatized muscle, angioid streaks, diabetes mellitus type I and II, cardiovascular disorder, calciphylaxis, calciphylaxis secondary to chronic kidney disease, calcific uremic arteriolopathy or atherosclerosis.

  公开号：

  WO2022079653A1

文献信息

• Averbuch-Pouchot, M. T.; Durif, A., European Journal of Solid State and Inorganic Chemistry
  作者：Averbuch-Pouchot, M. T.、Durif, A.

  DOI：——

  日期：——
• [EN] ORAL PYROPHOSPHATE FOR USE IN REDUCING CALCIFICATION<br/>[FR] PYROPHOSPHATE ORAL DESTINÉ À ÊTRE UTILISÉ DANS LA RÉDUCTION DE LA CALCIFICATION
  申请人：[en]PYROGENYX INC.

  公开号：WO2022079653A1

  公开（公告）日：2022-04-21

  The current invention relates to use of oral pyrophosphate wherein said pyrophosphate is selected from the group consisting of monoarginine pyrophosphate, monolysine pyrophosphate, dipotassium pyrophosphate, bisethanolamine pyrophosphate and bisammonium pyrophosphate for preventing and/or reducing tissue calcification, particularly soft tissue calcification, and/or diseases or disorders characterized by low plasma PPi levels, as, e.g., occurs in chronic kidney disease (CKD), end-stage renal disease (ESRD), generalized arterial calcification of infancy (GACI), Pseudoxanthoma elasticum (PXE), Arterial Calcification Due to Deficiency of CD73 (ACDC), Ehlers-Danlos syndrome, arteriosclerosis obliterans, venous calcifications, crystal deposition disorders, calcification resulting from neurological disorders, calcinosis universalis, calcinosis circumscripta, scleroderma, dermatomyositis, systemic lupus erythematosus, hyperparathyroidism, neoplasms, milk-alkali syndrome, hypervitaminosis D, tumoral calcinosis, hypophosphatemic rickets, ossification of the posterior longitudinal ligament of the spine, myocardial ischemia, joint calcification, heterotropic ossification of traumatized muscle, angioid streaks, diabetes mellitus type I and II, cardiovascular disorder, calciphylaxis, calciphylaxis secondary to chronic kidney disease, calcific uremic arteriolopathy or atherosclerosis.